Devonian Health Group Inc. (DVHGF)
USD 0.13
(-6.29%)
USD 0.13
(-6.29%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.71 Million CAD | -84.99% |
| 2022 | -2 Million CAD | -63.36% |
| 2021 | -1.22 Million CAD | 56.31% |
| 2020 | -2.81 Million CAD | -29.04% |
| 2019 | -2.18 Million CAD | 0.86% |
| 2018 | -2.28 Million CAD | -28.07% |
| 2017 | -1.71 Million CAD | -18.55% |
| 2016 | -1.44 Million CAD | -1527.86% |
| 2015 | -1.68 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -495.01 Thousand CAD | 22.81% |
| 2024 Q2 | -1.03 Million CAD | -109.26% |
| 2024 Q3 | -178.01 Thousand CAD | 82.82% |
| 2023 Q3 | -1.33 Million CAD | -50.81% |
| 2023 Q4 | -641.31 Thousand CAD | 51.88% |
| 2023 FY | - CAD | -84.99% |
| 2023 Q1 | -970.37 Thousand CAD | -90.77% |
| 2023 Q2 | -883.75 Thousand CAD | 8.93% |
| 2022 Q4 | -508.67 Thousand CAD | -136.22% |
| 2022 Q3 | -215.33 Thousand CAD | 76.09% |
| 2022 FY | - CAD | -63.36% |
| 2022 Q2 | -900.63 Thousand CAD | -128.18% |
| 2022 Q1 | -394.71 Thousand CAD | -130.6% |
| 2021 Q1 | -400.29 Thousand CAD | 34.65% |
| 2021 Q2 | -329.4 Thousand CAD | 17.71% |
| 2021 Q3 | -328.94 Thousand CAD | 0.14% |
| 2021 FY | - CAD | 56.31% |
| 2021 Q4 | -171.16 Thousand CAD | 47.96% |
| 2020 Q4 | -612.55 Thousand CAD | -39.82% |
| 2020 FY | - CAD | -29.04% |
| 2020 Q3 | -438.11 Thousand CAD | 47.81% |
| 2020 Q2 | -839.46 Thousand CAD | -40.75% |
| 2020 Q1 | -596.43 Thousand CAD | 27.37% |
| 2019 Q3 | -794.72 Thousand CAD | -1407.77% |
| 2019 Q4 | -821.18 Thousand CAD | -3.33% |
| 2019 FY | - CAD | 0.86% |
| 2019 Q1 | -250.92 Thousand CAD | 67.78% |
| 2019 Q2 | 60.76 Thousand CAD | 124.22% |
| 2018 Q3 | -398.61 Thousand CAD | 36.28% |
| 2018 Q4 | -778.85 Thousand CAD | -95.39% |
| 2018 FY | - CAD | -28.07% |
| 2018 Q1 | -485.56 Thousand CAD | 78.68% |
| 2018 Q2 | -625.53 Thousand CAD | -28.83% |
| 2017 Q3 | -453.24 Thousand CAD | -1251.05% |
| 2017 FY | - CAD | -18.55% |
| 2017 Q2 | -33.54 Thousand CAD | -1026.53% |
| 2017 Q1 | -2978.00 CAD | 54.54% |
| 2017 Q4 | -2.27 Million CAD | -402.44% |
| 2016 Q4 | -6551.00 CAD | 82.3% |
| 2016 Q2 | -68.76 Thousand CAD | -21.97% |
| 2016 FY | - CAD | -1527.86% |
| 2016 Q1 | -56.38 Thousand CAD | -100.39% |
| 2016 Q3 | -37.02 Thousand CAD | 46.17% |
| 2015 Q2 | -13.37 Thousand CAD | 67.51% |
| 2015 Q4 | -28.13 Thousand CAD | -344.26% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q1 | -41.16 Thousand CAD | 0.0% |
| 2015 Q3 | -6333.00 CAD | 52.65% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -165.121% |
| CSL Limited | 4.78 Billion USD | 100.078% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 94.768% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 37.316% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1454.038% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 78.604% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 103.952% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -141.951% |
| Mesoblast Limited | -62.38 Million USD | 94.043% |
| Marizyme, Inc. | -34.28 Million USD | 89.159% |
| Genus plc | 73.7 Million USD | 105.043% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 43.788% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -4.778% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 57.632% |
| ContraFect Corporation | -64.99 Million USD | 94.282% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 17.889% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -35.52 Million USD | 89.538% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -59.93% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -617.404% |
| Accustem Sciences Inc. | -3.74 Million USD | 0.799% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 92.294% |
| EV Biologics, Inc. | -1.26 Million USD | -193.299% |
| Q BioMed Inc. | -617.62 Thousand USD | -501.735% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 204.045% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -62.683% |
| Biomind Labs Inc. | -1.03 Million USD | -259.237% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 48.103% |
| Skye Bioscience, Inc. | -13.54 Million USD | 72.567% |
| SQZ Biotechnologies Company | -64.14 Million USD | 94.206% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -14765.928% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 4.321% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -40.539% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 76.581% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -487.673% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 137.628% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -149.862% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -48.543% |
| GB Sciences, Inc. | -1.41 Million USD | -161.745% |
| Alpha Cognition Inc. | -9.7 Million USD | 61.708% |
| argenx SE | -216.02 Million USD | 98.28% |
| HST Global, Inc. | -5303.00 USD | -69982.632% |
| Halberd Corporation | -74.27 Thousand USD | -4903.409% |
| Enzolytics Inc. | -2.12 Million USD | -75.138% |
| Resverlogix Corp. | -11.74 Million USD | 68.349% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -21.334% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 93.284% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 90.624% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 405.381% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -28.495% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 141.976% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 55371.892% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -147.946% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1081.006% |
| AVAX Technologies, Inc. | -6.11 Million USD | 39.2% |
| ONE Bio Corp. | 13.61 Million USD | 127.301% |
| Zenith Capital Corp. | -8.6 Million USD | 56.815% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.506% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -21233.345% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -51.913% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -2011.345% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -93.475% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -80.675% |
| Agentix Corp. | -1.37 Million USD | -170.929% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -2.62 Million USD | -41.614% |
| Helix BioMedix, Inc. | -1.04 Million USD | -255.198% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -112.371% |
| BioStem Technologies, Inc. | -7.55 Million USD | 50.799% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1952.307% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 1001.44% |
| Cell Source, Inc. | -4.27 Million USD | 13.014% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -912.056% |
| Regen BioPharma, Inc. | 1.46 Million USD | 353.519% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -296.658% |
| NovAccess Global Inc. | -1.03 Million USD | -259.151% |
| Affymax, Inc. | -14.29 Million USD | 74.002% |
| Itoco Inc. | -1.86 Million USD | -98.849% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -879.001% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -233.018% |
| CytoDyn Inc. | -18.02 Million USD | 79.386% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -4602.681% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -30290.727% |
| Qrons Inc. | -40.08 Thousand USD | -9172.428% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -665.215% |
| SYBLEU INC | -141.57 Thousand USD | -2525.172% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 804.636% |
| Rebus Holdings, Inc. | -951 Thousand USD | -290.797% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -249.948% |
| Mobile Lads Corp. | -2.24 Million USD | -65.829% |
| International Stem Cell Corporation | 202 Thousand USD | 1939.843% |
| Bioxytran, Inc. | -3.82 Million USD | 2.714% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6960.186% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -50.958% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 89.639% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -8158.849% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -35.737% |
| Neutra Corp. | -181.24 Thousand USD | -1950.507% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 81.564% |
| PureTech Health plc | -11.62 Million USD | 68.036% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 81.563% |
| IXICO plc | -707 Thousand USD | -425.669% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 51.64% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 92.313% |
| CSL Limited | 4.73 Billion USD | 100.079% |
| Cellectis S.A. | -92.63 Million USD | 95.988% |